Introduction
Extracellular proteinases are required for numerous developmental and disease-related processes. The ability to degrade extracellular proteins is essential for any individual cell to interact properly with its immediate surroundings, and for multicellular organisms to develop and function normally. Matrix metalloproteinase (MMP), zinc-dependent proteinases, is one of the potent extracellular matrixes that degrade enzymes. The MMP family currently consists of about 24 members that are characterized in humans, rodents, and amphibians. Initially, MMPs were classified according to their modular domain structure and ECM specificity (Egeblad and Werb, 2002) (Fig. 1) . In addition to their ECM substrates, MMPs also cleave cell surface molecules together with pericellular non-matrix proteins, thereby regulating cell behavior in several ways (McCawley and Matrisian, 2001; Sternlicht and Werb, 2001; Egeblad and Werb, 2002) . These substrates include an array of other proteinase, proteinase inhibitors, clotting factors, chemotactic molecules, latent growth factors, growth factor binding proteins, cell surface receptors, and cell-cell and cell-matrix adhesion molecules (Table 1) . Therefore, MMPs influence diverse physiologic and pathologic processes. In normal physiology, MMPs are involved in embryonic development, wound repair, ovulation, bone remodeling, macrophage function, and neutrophil function. MMPs also have important functions in pathologic conditions that are characterized by the excessive degradation of ECM, such as tumor metastasis, rheumatoid arthritis, periodontal disease, osteoarthritis, gastric ulcer, and arteriosclerosis (Westermarck and Kahari., 1999) . We focus here on the roles of MMPs in tumor cell metastasis.
Tumor Cell Metastasis and MMPs
Malignant disease is one of the most common causes of death. Most cancer patients do not die from local complications of their primary tumor growth, but rather from the development and spread of the tumor. Therefore, metastasis is a major cause of death among cancer patients. The development of metastasis consists of a complex series of linked, sequential steps, which tumor cells have to accomplish. They are as follows: (1 (Bohle and Kalthoff, 1999; Nash et al., 2002) (Fig. 2) .
MMPs are the main group of proteolytic enzymes that are involved in the tumor invasion, metastasis, and angiogenesis in cancer (Westermarck and Kahari, 1999; Chang and Werb, 2001) . Among the previously reported human MMPs, MMP-2 (gelatinase A/ Mr 72,000 type IV collagenase) and MMP-9 (gelatinase B/ Mr 92,000 type IV collagenase) are abundantly expressed in various malignant tumors (Johnsen et al., 1998) . They are considered key enzymes for tumor invasion and metastasis (Liabakk et al., 1996) . Other MMPs are also involved in these processes. MMPs function in many steps of metastasis, as will be described later.
Tumor Cell Invasion, Migration and MMPs
Because of their ECM-degrading activity and the correlation between high levels of their activity and increased tumor metastasis, MMPs were initially thought to facilitate tumor cell metastasis by destroying the basement membrane and other components of ECM. High expression levels of certain MMPs are related to the tumor invasion capacity in vivo. This has been shown in laryngeal carcinoma with MMP-13 (Cazorla et al., 1998) , in esophageal carcinoma with high MMP-7, MMP-9 and MT1-MMP expression levels (Ohashi et al., 2000) , and in oral SCCs with high MMP-2, MMP-9, MMP-1, MMP-3, and MT1-MMP expressions (Kurahara et al.,1999) . The invasive behavior of gastric carcinoma is associated with the MT1-MMP expression (Bando et al., 1998) and bladder carcinoma with both the MMP-2 and the MT1-MMP expressions (Kanayama et al., 1998) . In papillary thyroid carcinoma, the high MMP-2 and MMP-9 expression levels correlate with invasion capacity and lymph node metastasis.
Throughout cancer progression, the microecology of the local host tissue is a consistently active participant in the evolving tumor. Invasion occurs at the tumor-host interface, where the tumor and stromal cells exchange enzymes and cytokines that modulate the local ECM and stimulate cell migration. For tumor invasion and migration, the tumor cells and host coordinately regulate matrix degradation, cell-cell attachments, and cell-matrix attachment. Similar mechanisms are shared by physiological and tumorigenic invasion. In either case, the rate-limiting step is the breakdown of connective tissue barriers, ECM, that comprise collagens, laminins, fibronectin, vitronectin, and heparan sulfate proteoglycans, which require the action of MMPs. The difference between them is that the physiological invasion is regulated, whereas the tumorigenic invasion appears to be perpetual. Initially, it was thought that ECM blocked tumor metastasis not only in the sense of being a physical barrier, but also because it forms a self-protective, apoptosis-resistant microenvironment. However, there is increasing evidence to suggest a supportive role for ECM components in metastasis. A recent study, based on the wholegenomic analysis of metastasis, revealed that the enhanced expression of several genes that are normally involved in the ECM assembly (such as the fibronectin gene) correlated with the progression to a metastatic phenotype . Degraded matrix increased the metastatic potential: the MMP-2-dependent cleavage of laminin-5 induced keratinocyte migration (Giannelli et al., 1997) , and the MT1-MMP cleavage of laminin-5 allowed the migration of a variety of cell types (Koshikawa et al., 2000) .
%HVLGHVGHJUDGLQJ ( What is the source of MMPs? In most malignant tumors, stromal fibroblasts are the primary source of MMPs. The infiltration of inflammatory cells is a prominent feature of many tumors. They also produce MMPs to the peritumoral environment. Inflammatory cells also produce cytokines, which enhance the expression of MMPs by tumor and stromal 
MMP-1,2,13 Pro-MMP-9,13 MMP-9,13 Entactin Aggrecan Tenascin cells. Tumor cells produce factors, such as chemokines, cytokines, and the extracellular matrix metalloprotease inducer (EMMPRIN), which in turn activates the tumor-cell invasion (Biswas et al., 1995; Westermarck et al., 2000; Sun and Hemler, 2001 ) through the up-regulation of MMPs. In turn, MMPs generate a chemotactic signal in several systems. MMP-9 is required for the release of vascular endothelial growth factor (VEGF) during long bone development. Then VEGF acts as a chemoattractant for osteoblast recruitment (Engsig et al., 2000) . In addition, MMP-3 releases an unidentified macrophage chemoattractant in a co-culture model of herniated disc resorption (Haro et al., 2000) . MMPs also play a role in dampening the chemotactic response. For example, the monocyte chemoattractant protein (MCP)-3 is cleaved and inactivated by MMP-2, attenuating chemotaxis and the inflammatory response (McQuibban et al., 2000) .
Roles of MMPs in Immunologic Escape in the Circulation and Extravasation
Once the tumor cell has entered the circulation, it is in danger of being recognized by immunocompetent cells, which are responsible for the elimination of circulating tumor cells. In order to be successful in the establishment of metastases, a tumor cell has to adopt certain mechanisms of immune escape. MMPs are involved in immune escape by the stimulation of cancer cell-platelet interactions and inhibition of functions, as well as the proliferation of immune responsible cells, such as the T cell and natural killer cells.
It is well documented that platelets play an integral role in the hematogenous spread of cancerous cells during the metastatic cascade (Nash et al., 2002) . Human tumor cells are frequently found in association with thrombi. The ability of malignant tumor cells to aggregate platelets confers a number of advantages to the successful metastasis of cancer cells (Nieswandt et al., 1999) . When covered with a coat of platelets, a tumor cell acquires the ability to evade the bodys immune system (Philippe et al., 1993) . Another survival advantage for the tumor cell is the tendency for the large tumor-platelet aggregate to embolize the microvasculature at a new extravasation site (Malik, 1983) . Furthermore, platelets facilitate the extravasation of tumor cells (Mehta, 1984) . The success of circulating metastases relies on extravasation, which means that the tumor cell must slow down to attach to the vascular endothelium. However, in blood that flows at a normal rate, shear forces oppose cell attachment. The cells must, therefore, be equipped with adhesive mechanisms (Konstantopoulos and McIntire, 1997) . The platelet enables tumor cell extravasation that facilitates the adhesion of tumor cells to the vascular endothelium. MMP is found to stimulate platelet aggregation; therefore, the tumor cell metastatic potential increases (Sawicki et al., 1997 
Angiogenesis and MMPs
The process of angiogenesis is governed by an integrated signaling circuitry, and its modulation is dependent upon soluble angiogenic factors, cytokines, and insoluble ECM components that surround the participating vessels (Cho et al., 2002) . Angiogenesis is necessary for persistent tumor growth, because the sprouting capillaries are conduits for gas exchange and nutrient supply (Carmeliet and Jain, 2000) . Without vascular growth, the tumor mass is restricted to within a tissue-diffusion distance of approximately 0.2 mm. Tumor vessels are recruited by sprouting or intussusception from pre-existing vessels, in which interstitial tissue columns are inserted into the lumen of pre-existing vessels and partition the vessel lumen. MMPs are essential regulators during various phases of the angiogenic process-from the deposition and breakdown of the basement membrane of vascular structures (depending on the effects of MMPs on the matrix substrates) to the endothelial cell proliferation and migration (depending on the mobilization of the latent growth factors and receptor shedding) (Pepper, 2001 ). Many in vivo and in vitro experiments identified the involvement of MMPs in tumor vascularization. The head and neck carcinomas that are negative for MMP-9 have smaller microvessel density than positive tumors (Riedel et al., 2000) . The role of MMPs in angiogenesis has also been implicated in studies with knockout mice. Disturbed angiogenesis has been noted in mice that lack MMP-2, -9 and MT1-MMP (Hiraoka et al., 1998; Itoh et al., 1998 Itoh et al., , 1999 Bergers et al., 2000; Zhou et al., 2000) . The inhibition of angiogenesis was also detected in in vivo studies by the treatment of tumor-bearing animals with MMP inhibitors. The inhibition of angiogenesis in vivo has been shown at least with MMP inhibitors prinomastat, BAY 12-9566, batimastat, BMS-275291, neovastat, and metastat (Ferrante et al., 1999; Gatto et al., 1999; Shalinsky et al., 1999; Silvestre et al., 2001) .
Based on recent findings, a model to explain the role of MMPs during angiogenesis in cancer is described (Nguyen et al., 2001) . Endothelial cells continually secrete latent MMP-2 under basal conditions in vitro. In vivo, MMP-2 was found to be strongly expressed by some endothelial cell types, including human glioblastomas (Vince et al., 1999) . Thrombin, which is present at high levels in angiogenic situations such as cancer (Wojtukiewicz et al., 1993; EvenRam et al., 1998) and rheumatoid arthritis (Morris et al., 1994) , interacts with thrombomodulin on the endothelial surface and activates protein C. This rapidly activates latent MMP-2, which causes disruption of the existing capillary bed. The effect of thrombin is likely to be short-lived as it is readily incorporated into fibrin clots, immobilized in the subendothelial basement membrane, or inactivated by agents such as antithrombin III, protein C inhibitor, heparin co-factor II or heparin. Other angiogenic agents (such as hydrogen peroxide and the hepatocyte growth factor) may also contribute to the activation of MMP-2. As endothelial cells migrate during this initial phase of angiogenesis, MMP-9 may participate in the degradation of the basement membrane. It is feasible that MMP-9 is secreted from the storage vesicles within the cell in short bursts in order to locally degrade the basement membrane.
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MMPs and Tumor Growth and Progression
The evidence of tumor growth promotion by MMPs came from studies of MMPs knockout mice and their endogenous tissue inhibitors (TIMPs). Mice that lack MMP-7 show a reduction in intestinal tumorigenesis (Pozzi et al., 2000) . MMP-11 knockout mice show reduced tumorigenesis in response to chemical mutagenesis (Masson et al., 1998) . MMP-9-deficient mice show a reduced formation of melanoma metastases (Itoh et al., 1999) . MMP-2-deficient mice show reduced melanoma tumor progression and angiogenesis (Itoh et al., 1998) . Transgenic technology revealed the TIMP/MMP action. For example, the antisensemediated reduction of TIMP-1 resulted in a more rapid tumor initiation and progression (Martin et al., 1996) , and the TIMP-1 overproduction slowed chemical carcinogenesis in the skin (Buck et al., 1999) , as well as SV40 large T antigen-induced liver carcinogenesis in transgenic mice (Martin et al., 1996) . Therefore, these results suggest that MMPs are important contributors to tumor growth and progression.
How can MMPs promote tumor cell growth? Successful tumor cells are those that induce the release of growthstimulating signals from neighboring cells. The release of the extracellular domains of proteins from the cell surface by a mechanism that involves metalloprotease-directed proteolysis is referred to as ectodomain shedding. In addition to ectodomain shedding, the release from matrix binding also serves as a major mechanism for making growth regulators bioavailable to cells that are not in direct physical contact. MMPs participate in cell-surface proteolysis, leading to the release of a growing list of cell-surface growth regulators. Because MMPs degrade proteins in ECM, their primary function was considered to be the remodeling of ECM. However, MMPs also act on the non-matrix substrates (e. g., chemokines, growth factors, growth factor receptors, adhesion molecules, and apoptotic mediators) that yield the rapid and critical cellular responses that are required for tumor growth and progression. For example, MMP-2 influences the cellsurface receptor-mediated signaling by releasing the active ectodomain of the fibroblast growth factor receptor 1 (FGFR-1) (Levi et al., 1996) . The coordinated regulation of MMPs and TIMPs, therefore, governs the cleavage and release of many important growth factors and cell-surface receptors. (Kahari and Saarialho-Kere, 1999) . In addition to TIMPs, the α1-proteinase inhibitor and α2-macroglobulin, the C-terminal fragment of procollagen C RECK is a 110-kDa glycoprotein that contains a serineprotease inhibitor-like domain, two domains that contains the epidermal growth factor (EGF)-like repeats, and a C-terminal domain the encodes a glycosylphosphatidylinositol (GPI) modification that anchors RECK to the plasma membrane (Takahashi et al., 1998) . RECK regulates at least three members of the MMP family-MMP-2, MMP-9, and MT1-MMP-by various mechanisms (Takahashi et al., 1998; Oh et al., 2001) . Membrane-anchored RECK inhibits the secretion of proMMP-9; whereas, both the membrane-anchored and soluble RECK directly inhibit the MMP-2, -9, and MT1-MMP catalytic activity. In addition, RECK inhibits both of the catalytic steps of the proMMP-2 activation. By inhibiting the MT1-MMP activity, RECK inhibits the processing of proMMP-2 to the intermediate species. RECK also inhibits the final processing step of proMMP-2, where the intermediate-processed form is autolytically activated. In the context of tumor development, the overexpression of RECK in HT1080 cells results in the attenuated-tumor formation in nude mice as a consequence of the limited-angiogenic sprouting (Oh et al., 2001) . Since the balance between the ECM deposition and degradation is the key for endothelial cell homeostasis, then it is probable that RECK contributes functionally to vasculogenesis and angiogenesis by attenuating the degradation of MMP substrates (Rhee and Coussens, 2002) .
Regulation of MMPs

Conclusions
MMPs play a crucial role in every step of tumor metastasis. Originally, it was thought that MMPs increase the metastatic potential through the degradation of the extracellular matrix. Much evidence shows that MMPs also control non-matrix substrates, such as growth factors and cell surface receptors. In turn, the multiple extracellular factors (including cytokines, growth factors, and interactions with adjacent cell and ECM) regulate MMPs expressions and activities. 
